Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | MPN updates: personalized prognostication, novel treatments & more

Ruben Mesa • 18 Jan 2019
ASH 2018
Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Azacitidine Decitabine Fedratinib Imetelstat Momelotinib Pacritinib Peginterferon alfa-2a PRM-151 Ruxolitinib Thalidomide

Ruben Mesa, MD, of the UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, shares his view on the highlights for myeloproliferative neoplasms (MPNs), including novel treatments, outlooks, and individualized prognostication, from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Ruben Mesa

2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
2:08
Real-world analysis of the MOST study: factors impacting progression to MF in patients with ET
Ruben Mesa • 9 Dec 2023
2:26
Assessing the impact of momelotinib on transfusion burden in MF: analysis of SIMPLIFY-1 & MOMENTUM
Ruben Mesa • 9 Dec 2023
2:20
Quantifying the anemia benefit of momelotinib in MF: analysis of data from SIMPLIFY-1 & SIMPLIFY-2
Ruben Mesa • 9 Dec 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals